MAJEPTIL 10 MG
THIOPROPERAZINE (THIOPROPERAZINE MESYLATE) : 10 MG · DIN 01927639 · SEARCHLIGHT PHARMA INC
Health Canada status: CANCELLED POST MARKET
What is MAJEPTIL?
MAJEPTIL 10 MG contains THIOPROPERAZINE (THIOPROPERAZINE MESYLATE) : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 01927639, held by SEARCHLIGHT PHARMA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 18-Jul-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is MAJEPTIL used for?
All types of acute and chronic schizophrenia, including treatment-resistant cases; manic syndromes.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 01927639 |
|---|---|
| Brand name | MAJEPTIL |
| Generic / active ingredient | THIOPROPERAZINE (THIOPROPERAZINE MESYLATE) : 10 MG |
| Manufacturer | SEARCHLIGHT PHARMA INC |
| Strength | 10 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N05AB08 THIOPROPERAZINE |
| AHFS class | 28:16.08.24 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 18-Jul-2024 |
| Original market date | 1962-12-31 00:00:00 |
How is it administered?
Adults: Start 5 mg/day, increase to 30-40 mg/day. Children >10: Start 1-3 mg/day. Maintenance: lowest effective level. Discontinuous treatment reserved for resistant cases.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Protect from light. Store between 15 – 30 °C.
How is it supplied?
Bottles of 100 tablets.
Contraindications
Comatose/depressive states; Parkinson's disease; blood dyscrasias; spastic diseases; senile patients with Parkinson-like symptoms; children under 3; sensitivity to phenothiazines.
Warnings and precautions
Increased mortality in elderly with dementia. Risk of Neuroleptic Malignant Syndrome, Tardive Dyskinesia, QT prolongation, and Venous Thromboembolism. May impair driving ability.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.